Ceapro, Inc. is a biotechnology company, which is involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its extracts are also used in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company specializes in natural product chemistry, microbiology, biochemistry, immunology, and process engineering in the fields of active ingredients, biopharmaceuticals, and drug-delivery solutions. Ceapro was founded on January 1, 1997 and is headquartered in Edmonton, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone780-421-4555
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.94 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/27/2019 (Estimated)
OptionableNot Optionable
Ceapro (OTCMKTS:CRPOF) Frequently Asked Questions
What is Ceapro's stock symbol?
Ceapro trades on the OTCMKTS under the ticker symbol "CRPOF."
How were Ceapro's earnings last quarter?
Ceapro Inc (OTCMKTS:CRPOF) announced its quarterly earnings results on Thursday, May, 23rd. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $2.41 million for the quarter. Ceapro had a negative net margin of 5.25% and a negative return on equity of 3.19%. View Ceapro's Earnings History.
When is Ceapro's next earnings date?
Has Ceapro been receiving favorable news coverage?
Media stories about CRPOF stock have trended somewhat positive on Thursday, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ceapro earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Ceapro.
Who are some of Ceapro's key competitors?
Some companies that are related to Ceapro include Fortress Biotech (FBIO), Ovid Therapeutics (OVID), Cumberland Pharmaceuticals (CPIX), Aclaris Therapeutics (ACRS), Avadel Pharmaceuticals (AVDL), Catabasis Pharmaceuticals (CATB), Correvio Pharma (CORV), Aridis Pharmaceuticals (ARDS), Tiziana Life Sciences (TLSA), Spring Bank Pharmaceuticals (SBPH), Entasis Therapeutics (ETTX), Inflarx (IFRX), China SXT Pharmaceuticals (SXTC), Unum Therapeutics (UMRX) and Scpharmaceuticals (SCPH).
Who are Ceapro's key executives?
Ceapro's management team includes the folowing people:
- Gilles R. Gagnon, President, Chief Executive Officer & Director
- Stacy Prefontaine, Chief Financial Officer & Secretary
- Leoni DeJoya, Vice President-Bioprocessing Business Unit
How do I buy shares of Ceapro?
Shares of CRPOF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ceapro's stock price today?
One share of CRPOF stock can currently be purchased for approximately $0.2925.
How big of a company is Ceapro?
What is Ceapro's official website?
How can I contact Ceapro?
Ceapro's mailing address is 7824 51 Avenue NW, Edmonton A0, T6E 6W2. The company can be reached via phone at 780-421-4555 or via email at [email protected]
MarketBeat Community Rating for Ceapro (OTCMKTS CRPOF)
MarketBeat's community ratings are surveys of what our community members think about Ceapro and other stocks. Vote "Outperform" if you believe CRPOF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRPOF will underperform the S&P 500 over the long term. You may vote once every thirty days.
